^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ERK1 inhibitor

    Related drugs:
    Apply
    A Phase 1B/2A Trial of Combination of ASTX727 with ASTX029 in Acute Myeloid Leukemia (NCT06113289)
    Phase 1/2
    M.D. Anderson Cancer Center
    Suspended
    Last update posted :
    02/12/2025
    Initiation :
    02/08/2024
    Primary completion :
    05/01/2027
    Completion :
    05/01/2029
    KRAS • NF1 • PTPN11
    |
    Inqovi (decitabine/cedazuridine) • beroterkib anhydrous (ASTX029)
    A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3) (NCT05039177)
    Phase 1/2
    Erasca, Inc.
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    09/20/2021
    Primary completion :
    08/01/2025
    Completion :
    12/01/2025
    KRAS • BRAF • NRAS
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Erbitux (cetuximab) • Ibrance (palbociclib) • Braftovi (encorafenib) • ERAS-007
    Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) (EAY131-Z1L) (NCT06400225)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    07/24/2019
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    BRAF
    |
    ulixertinib (BVD-523)
    Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults (NCT05804227)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/03/2024
    Initiation :
    04/20/2023
    Primary completion :
    09/22/2025
    Completion :
    09/22/2027
    NF1
    |
    NF1 mutation
    |
    ulixertinib (BVD-523)
    LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer (NCT04616183)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/30/2024
    Initiation :
    12/02/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    KRAS • BRAF • MAP2K1
    |
    Erbitux (cetuximab) • Verzenio (abemaciclib) • temuterkib (LY3214996) • Datalai (cetuximab biosimilar)
    LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients (NCT04391595)
    Phase 1
    Nader Sanai
    Recruiting
    Last update posted :
    03/27/2024
    Initiation :
    07/08/2020
    Primary completion :
    12/01/2024
    Completion :
    02/01/2025
    CDKN2A • CDK4 • CDKN2B
    |
    CDK4 amplification
    |
    Verzenio (abemaciclib) • temuterkib (LY3214996)
    Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy (NCT05985954)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    03/25/2024
    Initiation :
    01/18/2024
    Primary completion :
    03/28/2026
    Completion :
    03/28/2028
    KRAS • BRAF • NRAS
    |
    BRAF V600E • BRAF V600 • BRAF wild-type
    |
    Erbitux (cetuximab) • Braftovi (encorafenib) • ulixertinib (BVD-523)
    Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas (UTAH) (NCT04145297)
    Phase 1
    University of Utah
    Completed
    Last update posted :
    03/20/2024
    Initiation :
    03/17/2020
    Primary completion :
    06/10/2022
    Completion :
    08/18/2022
    KRAS • BRAF • HRAS • RAS
    |
    BRAF mutation
    |
    ulixertinib (BVD-523) • hydroxychloroquine
    Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies (NCT05221320)
    Phase 2
    BioMed Valley Discoveries, Inc
    Recruiting
    Last update posted :
    02/13/2024
    Initiation :
    05/26/2022
    Primary completion :
    12/06/2024
    Completion :
    03/19/2025
    KRAS • BRAF • MSI • HRAS • MAP2K1 • RAS • MAPK1 • MAPK3
    |
    MSI-H/dMMR
    |
    ulixertinib (BVD-523) • hydroxychloroquine
    JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations (NCT04418167)
    Phase 1
    JS InnoPharm, LLC
    Suspended
    Last update posted :
    02/02/2024
    Initiation :
    06/18/2020
    Primary completion :
    06/30/2024
    Completion :
    12/17/2024
    MAP2K1 • NF1 • RASA1
    |
    BRAF V600E • BRAF V600K
    |
    Tafinlar (dabrafenib) • JSI-1187